TSC22D3 and cancer: Four gene markers, BARD1 (BRCA-associated RING domain 1), SOD2 (superoxide dismutase 2), S100A10, and TSC22D3 (TSC22 domain family member 3), were found to be the targets of several approved cancer drugs.